Drugs / KML001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01110226 | Apr 2010 → Oct 2015 | lung carcinoma | University of Maryland, Baltimore | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KML001 | “KML001 (sodium metaarsenite) is an orally bioavailable arsenic compound that has entered phase I/II clinical trials in prostate cancer.” PMID 18628474 ↗ Jul 2008 |
| Modality | Small molecule | “KML001 (sodium metaarsenite) is an orally bioavailable arsenic compound” PMID 18628474 ↗ Jul 2008 |
| Route | Oral | “It should be taken by mouth immediately prior to cisplatin infusion.” NCT01110226 ↗ |